Egrifta
Payments companies reported to CMS as associated with Egrifta. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Egrifta, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Egrifta
These are the largest totals companies reported as associated with Egrifta. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Jihad Slim | Newark, NJ | Infectious Disease | $41,558.79 |
| Claudia Martorell | Springfield, MA | Infectious Disease | $22,518.83 |
| Daniel Lee | San Diego, CA | Internal Medicine | $18,617.83 |
| Zandraetta Tims-Cook | Atlanta, GA | Infectious Disease | $16,112.80 |
| Robin Beach | Houston, TX | Family | $15,610.92 |
| Gary Sinclair | Dallas, TX | Internal Medicine | $11,091.15 |
| Noah Lee | Oakland Park, FL | Family Medicine | $10,296.91 |
| Douglas Cunningham | Phoenix, AZ | Family Medicine | $9,334.58 |
| Ricky Hsu | New York, NY | Internal Medicine | $7,828.40 |
| Marc Tribble | Dallas, TX | Internal Medicine | $6,623.63 |
Prescribed Egrifta?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.